Home › Employers › Teva Branded Pharmaceutical Products R&D LLC.
Teva Branded Pharmaceutical Products R&D LLC.: H-1B salaries and sponsorship
Teva Branded Pharmaceutical Products R&D LLC. filed 12 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 12. Median offered salary: $149,772.
Does Teva Branded Pharmaceutical Products R&D LLC. sponsor H-1B visas?
Teva Branded Pharmaceutical Products R&D LLC. filed 12 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 22, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Digital Bioprocess Engineer | 2 | $83,025 |
| Sr. Manager – Global Data, Analytics & Reporting | 1 | $134,000 |
| Associate Director | 1 | $173,500 |
| Scientist, Analytical Chemistry | 1 | $115,000 |
| Senior Director Research & Development, Analytical Sciences | 1 | $255,000 |
| Director, Process Development, Biologics CMC | 1 | $190,000 |
| Principal Statistician | 1 | $111,600 |
| Director, Biostatistics | 1 | $190,026 |
| Sr Research Associate, Immunogenicity | 1 | $101,111 |
| Sr Manager, Translational Statistics and Bioinformatics | 1 | $165,545 |
| Senior Director, Drug Substance Development, R&D | 1 | $240,345 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 5 | $173,500 |
| FY2024 | 1 | $111,600 |
| FY2026 | 6 | $133,328 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
- Natural Sciences Managers5
- Medical and Clinical Laboratory Technologists2
- Market Research Analysts and Marketing Specialists1
- Biochemists and Biophysicists1
- Statisticians1
- Microbiologists1
- Molecular and Cellular Biologists1
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Senior Director, Drug Substance Development, R&D | $240,345 Level IV | West Chester, PA | Jun 22, 2026 | Nov 22, 2026 | Certified |
| Digital Bioprocess Engineer | $83,025 Level II | West Chester, PA | Jun 10, 2026 | Oct 1, 2026 | Certified |
| Sr Manager, Translational Statistics and Bioinformatics | $165,545 Level IV | West Chester, PA | Apr 22, 2026 | Oct 1, 2026 | Certified |
| Sr Research Associate, Immunogenicity | $101,111 Level III | West Chester, PA | Apr 22, 2026 | Oct 1, 2026 | Certified |
| Digital Bioprocess Engineer | $83,025 Level IV | West Chester, PA | Apr 22, 2026 | Oct 1, 2026 | Certified, then withdrawn |
| Director, Biostatistics | $190,026 Level III | West Chester, PA | Apr 1, 2026 | Sep 24, 2026 | Certified |
| Principal Statistician | $111,600–$167,400 Level II | West Chester, PA | Sep 27, 2023 | Oct 1, 2023 | Certified |
| Director, Process Development, Biologics CMC | $190,000–$215,000 Level IV | West Chester, PA | Sep 7, 2023 | Nov 22, 2023 | Certified |
| Associate Director | $173,500–$186,300 Level III | West Chester, PA | May 19, 2023 | May 22, 2023 | Certified |
| Senior Director Research & Development, Analytical Sciences | $255,000–$290,000 Level IV | West Chester, PA | Apr 19, 2023 | Oct 1, 2023 | Certified |
| Sr. Manager – Global Data, Analytics & Reporting | $134,000–$145,366 Level IV | Parsippany, NJ | Oct 18, 2022 | Oct 31, 2022 | Certified |
| Scientist, Analytical Chemistry | $115,000–$138,000 Level I | West Chester, PA | Apr 5, 2022 | Apr 13, 2022 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).